Why did we invest?
Groundbreaking technologies
Kneu Health stood out as a transformative digital health platform tackling neurological conditions, specifically Parkinson's disease and dementia, that affect millions globally yet remain underdiagnosed and undertreated. As an Oxford University spin-out leveraging over a decade of research and 420,000+ digital measures, Kneu has developed the world's first smartphone-based, FDA-cleared medical device for neurology monitoring. Its ability to combine motor, cognitive, and behavioural data creates the most comprehensive remote neurology dataset globally, directly addressing the £96 billion annual cost of neurological conditions in the UK alone.
Regulatory and commercial validation
Kneu Health's proven commercial traction and regulatory advantages has impressed us. Since spinning out in 2022, the company has secured live contracts with multiple NHS trusts, onboarded thousands of patients, and demonstrated measurable outcomes including neurology resource time savings and improvements in patient quality of life. With regulatory clearances and key partnerships with leading institutions like Oxford University and Cedars-Sinai, Kneu is uniquely positioned to scale in both UK and US markets. By partnering with Kneu Health, we are excited to support a purpose-driven company that not only addresses a critical unmet medical need but also has the potential to redefine neurological care globally.
Key Impact areas
Transforming care delivery
The platform delivers measurable efficiency gains, including neurology resource time savings and improved visit efficiency, addressing critical specialist shortages across both NHS and US health systems. Kneu's remote monitoring capabilities help stretch limited specialist resources whilst maintaining high-quality care standards
Reducing burden on health system
By combining over 500,000 digital measures into longitudinal datasets, Kneu enables clinicians to make more informed treatment decisions and optimise medication management effectively. The platform's AI-driven insights predict risk scores for disease progression, allowing for earlier interventions and more precise therapeutic adjustments based on objective data rather than subjective clinical assessments alone
Driving evidence-based decision making
Kneu Health is revolutionising neurological care by offering the world's first smartphone-based FDA-cleared monitoring platform for Parkinson's and dementia patients, improving clinical outcomes. By combining motor, cognitive, and behavioural assessments through daily smartphone activities, the platform enables clinicians to track disease progression objectively and provide personalised care, fundamentally changing how neurology care is delivered from reactive to proactive management
